Methylene Blue

Overview

Methylene blue is a synthetic phenothiazine (thiazine) dye and redox agent — a small molecule, not a peptide. Unlike most research compounds it is a fully FDA-approved prescription drug: Provepharm's ProvayBlue was approved in 2016 as the first-line antidote for acquired methemoglobinemia, and it is also used as a surgical dye and for vasoplegic syndrome. Separately, a large consumer market promotes low-dose methylene blue for cognition/energy — that use is investigational and off-label and should not be conflated with the approved antidote use.

Mechanism

Methylene blue's defining property is that it is a redox electron cycler, shuttling between oxidized (blue) and reduced (colorless) forms. In red cells it accepts electrons from NADPH (via G6PD-dependent pathways) and reduces ferric methemoglobin back to functional hemoglobin — the basis of its antidote use. It is also a potent reversible MAO-A inhibitor (the basis of its dangerous serotonergic interaction), inhibits nitric oxide/soluble guanylate cyclase (rationale in vasoplegia), and at low concentrations can act as an alternative mitochondrial electron carrier — the hypothesis behind its investigational cognitive effects. The dose-response is biphasic: high doses can paradoxically cause methemoglobinemia.

Clinical evidence

Methylene blue has a strong human evidence base for its approved/established uses and a thin one for the nootropic claims. For methemoglobinemia, decades of use plus the FDA label support it as first-line therapy (1-2 mg/kg IV). For low-dose cognition, the most-cited study is a randomized, double-blind, placebo-controlled fMRI trial (Rodriguez 2016, n=26) showing increased task-related brain activity and a small memory improvement after a single dose — a real but single, acute result, not evidence of durable benefit. Note the related compound TRx0237 (a methylene-blue derivative) gave largely disappointing Alzheimer's-trial results.

Safety profile

Methylene blue is a real drug with serious interactions. As a potent MAO-A inhibitor it can precipitate serious or fatal serotonin syndrome when combined with serotonergic drugs (SSRIs/SNRIs/MAOIs, certain opioids) — a boxed warning on the FDA label. It is contraindicated in G6PD deficiency (severe hemolytic anemia). High doses can paradoxically cause methemoglobinemia, and it commonly turns urine and body fluids blue-green and can interfere with pulse-oximetry. It is FDA-approved (prescription) and not WADA-prohibited (though a high-volume IV infusion is a banned method). Research-use framing; nothing here is medical advice or a dosing recommendation.

Compare

• vs Glutathione

  Both touch cellular redox biology, but methylene blue is an FDA-approved redox-cycling drug with serious interactions, whereas glutathione is an antioxidant supplement whose main risks come from the unregulated IV cosmetic route.

• vs NAD+

  Both are marketed for mitochondrial energy support and are sometimes stacked, but NAD+ is an endogenous redox coenzyme with weak human benefit evidence, while methylene blue is an approved drug whose nootropic use rests on a single acute fMRI study.